enVVeno Medical Corporation — 2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023; filed February 29, 2024. The company is a late clinical-stage medical-device developer and reported no operating revenue.
Business context
enVVeno is developing bioprosthetic replacement venous valves for severe chronic venous insufficiency (CVI). Its lead candidate, the surgically implanted VenoValve, was evaluated in the U.S. SAVVE pivotal study. The second candidate, the minimally invasive transcatheter enVVe, remained in preclinical development. Neither product had FDA approval.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $13.6 million | $9.9 million |
| Selling, general and administrative expense | $11.7 million | $15.0 million |
| Loss from operations | $25.2 million | $24.9 million |
| Other income | $1.7 million | $0.3 million |
| Net loss | $23.5 million | $24.7 million |
| Net loss per share | $1.91 | $2.20 |
| Cash used in operating activities | $18.9 million | $15.6 million |
At year-end, cash and cash equivalents were $3.6 million and short-term investments were $42.8 million, totaling $46.4 million. Working capital was $45.6 million. Total assets were $48.6 million and total liabilities were $2.4 million, including $1.4 million of operating lease liabilities; the filing reports no material borrowings. The facility lease runs through September 2027.
The company raised $25.8 million net in an October 2023 financing, issuing approximately 3.8 million common shares along with warrants. Outstanding common shares increased from 9.472 million at year-end 2022 to 13.317 million at year-end 2023. Cash burn was approximately $4 million–$5 million per quarter; management expected it to rise to $5 million–$6 million per quarter in 2025 and stated available resources should fund operations through late 2025. Management also said resources were sufficient to meet obligations for at least one year after the report date. These estimates depend on operating assumptions and do not remove the need for future financing.
Gross margin is not applicable because the company had no revenue. No profitability or revenue guidance was provided.
Material changes versus 2022
- R&D expense rose 37%, primarily from higher SAVVE trial costs ($6.2 million versus $3.5 million) and increased staffing.
- SG&A expense fell 22%, mainly because share-based compensation expense declined by $3.6 million.
- Operating cash use increased by $3.2 million, to $18.9 million.
- Net loss narrowed by $1.2 million, helped by a $1.5 million increase in other income, despite higher operating expenses.
- Cash and investments increased to $46.4 million from $39.0 million, alongside the 2023 financing. The company reported $17.1 million of outstanding warrants at year-end, in addition to options and restricted stock units, creating potential dilution.
Clinical progress, outlook, risks and contingencies
- VenoValve: SAVVE enrolled all 75 planned participants in October 2023, earlier than expected. Preliminary 30-day device-related major adverse-event data showed an 8% rate; the report described six mild DVTs and no deaths or pulmonary embolisms. The filing expected initial topline rVCSS efficacy data on March 6, 2024. FDA-required one-year data for all participants meant the company expected to be eligible to submit a PMA application in Q4 2024; this is a projected filing timeline, not an approval date.
- enVVe: Management planned a six-month GLP animal study beginning in Q1 2024 and aimed to file for IDE approval for its TAVVE pivotal trial by year-end 2024. The company estimated a U.S. target market of approximately 3.5 million patients; this is a company estimate, not realized demand.
- Clinical context: In an 11-patient first-in-human study, the company reported one-year average improvements in rVCSS, reflux time and pain scores. The small, uncontrolled study does not establish pivotal-trial efficacy. Reported safety events included one occlusion associated with non-compliance with anticoagulation therapy.
- Key business risks: FDA approval and clinical outcomes are uncertain; the company has no commercial revenue or sales infrastructure and expects continuing losses. It may need additional capital, with potential dilution. It also relies on a limited number of suppliers for porcine tissue and other components and must scale manufacturing and establish reimbursement and hospital adoption if products are approved.
- Legal contingency: The company and its CEO are defending consolidated claims by a former CFO, and have asserted counterclaims. The company denied the allegations; the trial was scheduled for May 13, 2024. The potential loss could not be reasonably estimated and no amount was accrued.
- Other items: The company reported no off-balance-sheet arrangements. Its financial statements received an unqualified audit opinion, with no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness under the applicable exemption.
Important facts for investors to verify
- Whether SAVVE’s full efficacy and safety results support the intended PMA submission, and whether FDA requests additional data or changes the expected timeline.
- Actual cash use, investment liquidity and financing needs against management’s late-2025 runway estimate.
- The terms, exercise status and potential dilution from the substantial outstanding warrant and equity-award overhang.
- Progress and results of the enVVe animal study and the timing and acceptance of any IDE application.
- Developments in the former employee litigation, including any change to the trial schedule or financial exposure.
- Whether manufacturing capacity, supplier continuity, reimbursement and hospital adoption can support commercialization if either product is approved.